Abingworth

Investor type

VC

Founded

2007

AUM

$2 000 M

Location

London, England, United Kingdom

$0-1 m

Investment Ticket

3-5 years

Investment Horizon

Seed, Series B, Series A

Investment Stage

Sale to strategic investor, IPO

Exit Strategy

Profile

Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.

We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences.

BROAD STRATEGIC APPROACH
Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare.

Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.

We can help attract talent for boards and leadership teams, choose drug targets for novel platforms, devise plans for clinical development, navigate legal issues, advise on PR strategy and think through corporate development and exit strategies. Adding to our own knowledge, we have a wide network of leading scientific and industry experts. Our collective experience is offered to all portfolio companies.

Industry

Pharmaceuticals Medical Devices Biotechnology Healthcare Services HealthTech Software AI MedTech Technology Life Sciences Machine Learning (ML) Fintech

Region of investment

North America Europe

Abingworth Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
Abingworth Clinical Co-Development Fund
Venture Capital (VC)
Biotechnology
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$105 M
January 2016
Fund VII
Venture Capital (VC)
Healthcare Services
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$220 M
August 2017
Abingworth Bioventures VII
Venture Capital (VC)
Biotechnology
Healthcare Services
Pharmaceuticals
Life Sciences
Seed
Series A
North America
Europe
$5-10 m
$315 M
July 2018
Abingworth Bioventures VIII
Venture Capital (VC)
Biotechnology
Healthcare Services
Pharmaceuticals
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$465 M
February 2021
Abingworth Clinical Co-Development Co-Investment Fund
Venture Capital (VC)
Biotechnology
Fintech
Healthcare Services
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$356 M
October 2023

Contacts

Upgrade to see contacts
Name
Title
Email
avatar
jW13STtGJouLR80N jW13STtGJouLR80N
jW13STtGJouLR80N
avatar
jW13STtGJouLR80N jW13STtGJouLR80N
jW13STtGJouLR80N
avatar
jW13STtGJouLR80N jW13STtGJouLR80N
jW13STtGJouLR80N
avatar
jW13STtGJouLR80N jW13STtGJouLR80N
jW13STtGJouLR80N
avatar
jW13STtGJouLR80N jW13STtGJouLR80N
jW13STtGJouLR80N
If there are no contacts of this investor, please write to us, we will try to find them as soon as possible and get back to you!